A Study to Evaluate the Safety and Dosimetry of 68Ga-OncoACP3 in Patients With Prostate Cancer

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 8, 2025

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

Prostate CancerProstate Cancer Metastatic DiseasePSA Level Greater Than 0.2

Interventions

DRUG

[68Ga]Ga-OncoACP3

Single intravenous bolus injection.

Trial Locations (3)

RECRUITING

IRCCS Ospedale San Raffaele, Milan

RECRUITING

Fondazione IRCCS Istituto Nazionale dei Tumori, Milan

RECRUITING

ASST Papa Giovanni XXIII, Bergamo

All Listed Sponsors

lead

Philogen S.p.A.

INDUSTRY

NCT06840535 - A Study to Evaluate the Safety and Dosimetry of 68Ga-OncoACP3 in Patients With Prostate Cancer | Biotech Hunter | Biotech Hunter